CervoMed (CRVO) investor relations material

Executive summary

• Focused on developing neflamapimod, an oral small molecule for age-related brain disorders, with lead indication in dementia with Lewy bodies (DLB); progressing toward a Phase 3 DLB trial in the second half of 2026, pending financing.

• Completed Phase 2b RewinD-LB Trial for DLB, funded by a $21.3 million NIA grant, with no further grant funding available.

• Presented new MRI and biomarker analyses showing neflamapimod's potential to reverse disease progression and benefit early-stage DLB patients.

• Completed enrollment in a Phase 2a trial for non-fluent variant primary progressive aphasia (nfvPPA) in the US and began enrollment in the UK; neflamapimod selected for inclusion in the UK EXPERTS-ALS platform for ALS clinical testing.

• No products approved or revenue from product sales to date; expects continued operating losses and need for additional capital.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $12.9 million as of March 31, 2026, down from $20.9 million at year-end 2025.

• Net loss was $8.0 million for Q1 2026, compared to $4.9 million for Q1 2025.

• Research and development expenses increased to $5.1 million (up 6% year-over-year), and general and administrative expenses rose to $3.0 million (up 25%).

• No grant revenue recognized in Q1 2026, compared to $1.9 million in Q1 2025, due to completion of the RewinD-LB trial.

• Accumulated deficit reached $105.7 million as of March 31, 2026.

Outlook and guidance

• Current cash and equivalents are not expected to fund operations for twelve months from the report date, raising substantial doubt about going concern; cash runway expected to fund operations into Q3 2026 based on current plans.

• Plans to seek additional financing through equity, debt, or other arrangements; failure to secure funding may require delaying or terminating development activities.

• Plans to initiate Phase 3 DLB trial in the second half of 2026, subject to funding.

• Expects expenses to increase as clinical development progresses, especially for planned Phase 3 DLB trial.

• Anticipates completion of Phase 2a RESTORE trial for stroke recovery and topline data in the second half of 2026; expects to complete nfvPPA trial enrollment and report initial biomarker and topline data in mid to late 2026; first ALS patient dosing in EXPERTS-ALS platform expected by end of 2026.